D3-Pharmacy Aps Financials, key figures and credit report
Gross profit -2.7 kDKK FY 2025 +78% vs 2024
EBIT -3.0 kDKK FY 2025 +79.6% vs 2024
Net debt -10.6 kDKK FY 2025 -173.1% vs 2024
Quick ratio — FY 2025
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | -12.31 | ||||
| Gross profit | -2.66 | -10.09 | -10.99 | -12.31 | -2.71 |
| Employee benefit expenses | -5.00 | -5.00 | -5.00 | ||
| Total depreciation | -2.13 | -2.73 | -2.43 | -2.43 | -0.30 |
| EBIT | -9.79 | -17.82 | -8.43 | -14.74 | -3.01 |
| Other financial income | -4.31 | 4.32 | |||
| Other financial expenses | -0.65 | -3.06 | -2.10 | -2.17 | |
| Pre-tax profit | -9.79 | -22.79 | -7.17 | -16.84 | -5.18 |
| Income taxes | 2.62 | 5.00 | 1.58 | 3.71 | 1.14 |
| Net earnings | -7.17 | -17.79 | -5.59 | -13.14 | -4.04 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Development expenditure | 7.89 | ||||
| Intangible rights | 5.16 | 2.73 | 0.30 | ||
| Intangible assets total | 7.89 | 5.16 | 2.73 | 0.30 | |
| Tangible assets total | |||||
| Holdings in group member companies | 40.00 | 40.00 | 40.00 | 40.00 | |
| Investments total | 40.00 | 40.00 | 40.00 | 40.00 | |
| Non-current loans receivable | 244.35 | 244.35 | 244.35 | 244.35 | 244.35 |
| Long term receivables total | 244.35 | 244.35 | 244.35 | 244.35 | 244.35 |
| Inventories total | |||||
| Current other receivables | 859.52 | 3.54 | 33.29 | 30.17 | 18.57 |
| Current deferred tax assets | 201.19 | 206.19 | 207.77 | 211.47 | 212.61 |
| Short term receivables total | 1 060.71 | 209.73 | 241.05 | 241.64 | 231.17 |
| Cash and bank deposits | 143.18 | 540.49 | 17.43 | 3.89 | 10.62 |
| Cash and cash equivalents | 143.18 | 540.49 | 17.43 | 3.89 | 10.62 |
| Balance sheet total (assets) | 1 456.14 | 1 039.74 | 545.57 | 530.18 | 526.15 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Retained earnings | 473.87 | 466.70 | 448.91 | 443.32 | 430.18 |
| Profit of the financial year | -7.17 | -17.79 | -5.59 | -13.14 | -4.04 |
| Shareholders equity total | 566.70 | 548.91 | 543.32 | 530.18 | 526.15 |
| Non-current liabilities total | |||||
| Current trade creditors | 6.49 | 4.98 | |||
| Current owed to group member | 480.85 | ||||
| Other non-interest bearing current liabilities | 882.95 | 5.00 | 2.25 | ||
| Current liabilities total | 889.44 | 490.83 | 2.25 | ||
| Balance sheet total (liabilities) | 1 456.14 | 1 039.74 | 545.57 | 530.18 | 526.15 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated